The Estée Lauder Companies and BALMAIN are Partnering to Launch BALMAIN BEAUTY
26.9.2022 09:00:00 EEST | Business Wire | Press release
The Estée Lauder Companies Inc. (NYSE: EL) (“ELC”) and BALMAIN have entered into a license agreement to collaboratively develop, produce, and distribute an innovative line of beauty products that will speak to luxury consumers around the world: BALMAIN BEAUTY. The collaboration is expected to launch in fall 2024, with the goal to transform the luxury and couture beauty world through exceptional design, singular craftsmanship, and an unyielding commitment to innovation.
In 1945, when founder Pierre Balmain boldly introduced his audacious, fresh, and feminine “New French Style,” Balmain helped post-war Paris begin to regain its title as the fashion world’s capital. Today’s BALMAIN, under the visionary leadership of Creative Director Olivier Rousteing since 2011, builds upon Pierre Balmain’s legacy, with the house’s rich archives providing key inspirations and the legendary savoir-faire of Balmain’s atelier ensuring the success of Rousteing’s distinctive “Renewed French Style.” While revering the past, Rousteing has assumed a pioneering role in advocating for a more inclusive fashion world, while he and his team also expand design possibilities, relying on time-honored Parisian couture techniques to masterfully perfect the latest 21st-century breakthroughs.
Founded in 1946 by the remarkable female entrepreneur, Estée Lauder, today The Estée Lauder Companies is the global leader in prestige and luxury beauty, celebrating the diversity of the world and inspiring consumers to express their individual beauty. As the only company focused solely on prestige and luxury makeup, skin care, fragrance, and hair care, the company’s brands are sold in approximately 150 countries and territories. Infused throughout the family company are deep-rooted values and a rich history, as well as a passion for creativity and innovation and a desire to push boundaries and invent the unexpected. Drawing inspiration from the bold and breakthrough efforts of Estée Lauder, who helped invent the modern beauty industry, the company is at the forefront of social and environmental impact, with equity and sustainability as top priorities.
“For over ten years, my BALMAIN team and I have been pushing the boundaries of what is possible in fashion,” notes Mr. Rousteing. “We’ve been determined to reflect the way that today’s diverse generation wishes to live and dress. So, obviously, there was no way that we were going to expand into beauty without ensuring that we had found the partner who understood and shared our outlook. From the very beginning, the team at The Estée Lauder Companies made it very clear that they support BALMAIN’s distinctive vision, as well as our goal of disrupting the global luxury beauty paradigm. Knowing that — and knowing that Estée Lauder is the paragon of excellence — well, I can’t wait to start working with them.”
Guillaume Jesel will be appointed President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development, effective immediately. “BALMAIN and Olivier Rousteing are visionary forces in global fashion. We look forward to working with them to expand the BALMAIN universe and forge a new space in luxury beauty that clearly reflects the strong, inclusive, and fearless spirit of the brand,” said Mr. Jesel.
Follow on Instagram @Balmainbeauty.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies (“ELC”) is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, Aerin Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, Kilian Paris, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
About BALMAIN
For more than ten years, BALMAIN’s Creative Director, Olivier Rousteing, has been inventively building upon Pierre Balmain’s extraordinary legacy, while always remaining true to his own determination to design clothes that reflect the way his inclusive, powerful, and global BALMAIN customer wishes to live today. The result is a unique and instantly recognizable BALMAIN silhouette, style and attitude that highlights the singular craftsmanship of the house’s celebrated ateliers, while consistently referencing a rich Parisian heritage. For more information, please visit balmain.com.
[The forward-looking statements in this press release, including those in the quoted remarks and those relating to the expected launch and expectations for BALMAIN BEAUTY involve risks and uncertainties. Factors that could cause actual results to differ materially from those forward-looking statements include current economic and other conditions in the global marketplace, actions by retailers, suppliers and consumers, competition, the ongoing success of the collaborative relationship of the parties, the abilities to implement the plan, and those risk factors described in ELC’s annual report on Form 10-K for the year ended June 30, 2022.]
ELC-C
ELC-B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220925005060/en/
Contact information
Investor Relations:
Rainey Mancini
rmancini@estee.com
Media Relations:
Jill Marvin
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
